☆ 4.7 Review

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer

BIOMEDICINES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Cell Biology

Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements

Salima Akter et al.

Summary: This review discusses the current therapeutic strategies for ovarian cancer, novel drug-delivery systems, and potential biomarkers. It emphasizes the relationship between understanding disease biology and technological advancements, providing new hope for more accurate diagnosis and prognosis.

CELLS (2022)

添加到收藏夹

Article Obstetrics & Gynecology

Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer

Rami Vanguri et al.

Summary: This study quantitatively characterized the temporal and spatial expression changes of repressive and stimulatory checkpoints in immune cell populations in high grade serous ovarian carcinomas (HGSOC) before and after neoadjuvant platinum-based chemotherapy. The results showed that the expression of inhibitory and stimulatory proteins changed post-treatment, resulting in immune compositions more favorable to checkpoint modulations, suggesting potential therapeutic strategies for recurrent HGSOC.

GYNECOLOGIC ONCOLOGY REPORTS (2022)

添加到收藏夹

Review Oncology

New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors

Ana Luiza Gomes de Morais et al.

Summary: TIM-3 has been associated with advanced stages and shorter survival in several tumor types. Early clinical trials with anti-TIM-3 monoclonal antibodies have shown safety, but further investigations are needed to determine their antitumor activity. The TIM-3 pathway is complex, requiring the development of different inhibitors to overcome resistance.

CURRENT ONCOLOGY REPORTS (2022)

添加到收藏夹

Article Oncology

Intratumoral expression analysis reveals that OX40 and TIM-3 are prominently expressed and have variable associations with clinical outcomes in high grade serous ovarian cancer

Nicole E. James et al.

Summary: This study compared the expression levels of immune co-stimulatory and co-inhibitory receptors in high grade serous ovarian cancer (HGSOC) and found that TIM-3 and OX40 were the most abundant receptors. OX40 was also strongly associated with improved patient survival.

ONCOLOGY LETTERS (2022)

添加到收藏夹

Article Reproductive Biology

Peripheral lymphocyte populations in ovarian cancer patients and correlations with clinicopathological features

Shuang Ye et al.

Summary: Peripheral lymphocyte subsets undergo significant changes in ovarian cancer patients, with elevated levels of regulatory T cells and decreased levels of CD3(+)CD8(+) T and CD8(+)CD28(+) T cells. The decrease in B cell levels may be related to disease aggressiveness.

JOURNAL OF OVARIAN RESEARCH (2022)

添加到收藏夹

Article Cell Biology

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer

Pauline Weimer et al.

Summary: This study found a high prevalence of V δ1 T cells in the malignant ascites lymphocytes (MALs) and tumor infiltrating lymphocytes (TILs) of ovarian cancer patients. These cells exhibited different differentiation states, and V δ1 T cells in TILs showed the highest levels of expression for TIGIT, PD-1, and CD39, which provides hope for therapeutic strategies based on V δ1 T cells and these receptors.

CELLS (2022)

添加到收藏夹

Article Oncology

Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer

Kalika Kamat et al.

Summary: Macrophage-secreted CCL23 contributes to the immune-suppressive TME in ovarian cancer by inducing exhausted phenotype of CD8+ T cells.

BRITISH JOURNAL OF CANCER (2022)

添加到收藏夹

Article Pathology

Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy

Yubo Zhang et al.

Summary: This study found that LAG-3 expression is associated with clinicopathological parameters, immune cell infiltration, and relapse-free survival in patients with endometrial cancer. LAG-3 positivity is more common in patients with POLE mutation or mismatch repair deficiency, suggesting its potential as a target for immunotherapy and a predictor of prognosis.

PATHOLOGY RESEARCH AND PRACTICE (2022)

添加到收藏夹

Review Medicine, General & Internal

Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications

Lishu Zhao et al.

Summary: Immunotherapy targeting checkpoints has revolutionized cancer therapy, with LAG-3 being a key inhibitory checkpoint that plays a role in anti-tumor immunity. Increasing evidence suggests the potential of LAG-3 blockade in enhancing immune efficacy.

CHINESE MEDICAL JOURNAL (2022)

添加到收藏夹

Review Peripheral Vascular Disease

High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis

Annabelle Rodriguez

Summary: Recent studies have shown a U-shaped association between low HDL-C levels and increased risk for all-cause and cause-specific mortality, while high HDL-C levels do not provide cardioprotection. Genetic studies have identified specific genes associated with high HDL-C and increased risk for myocardial infarction. These findings suggest the need for revision of clinical CVD risk calculators.

CURRENT ATHEROSCLEROSIS REPORTS (2021)

添加到收藏夹

Review Oncology

TIM-3 pathway dysregulation and targeting in cancer

Amer M. Zeidan et al.

Summary: Dysfunction of the immune system is a hallmark of cancer, leading to the emergence of immunotherapy as a treatment modality. TIM-3 has been identified as a potential immune checkpoint target in both solid tumors and hematologic malignancies, suggesting its importance in cancer treatment.

EXPERT REVIEW OF ANTICANCER THERAPY (2021)

添加到收藏夹

Article Oncology

Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape

Felix Blanc-Durand et al.

Summary: This study investigated the expression of immune co-regulators in epithelial ovarian cancer (EOC) and found that TIM3 was the most prevalent co-regulator. Most ovarian tumors expressed 2 or more co-inhibitory molecules, but these biomarkers were not correlated with each other. Neoadjuvant chemotherapy significantly impacted the expression of immune co-regulators, and there was no significant difference in the pattern of co-regulator expression between platinum-sensitive and resistant patients.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Article Immunology

TIM-3: An update on immunotherapy

Lizhen Zhao et al.

Summary: TIM-3, originally found on Th1 cells, has been discovered to be expressed on various immune cells with different ligands and effects. It plays a significant role in autoimmune diseases, chronic viral infections and tumors. Targeting TIM-3 is a promising approach in current immunotherapy, especially in combination with other immune checkpoint blockers.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Review Immunology

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy

Yihang Qi et al.

Summary: LAG3 plays an important role in immunotherapy, and its combination therapy with PD-1/PD-L1 has shown significant synergistic effects. The combination of PD-1 pathway blockade with LAG3 inhibition may offer a new approach for the design of more effective and precise cancer immune checkpoint therapies.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Reproductive Biology

Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients

Jianfeng Zheng et al.

Summary: In this study, a risk model based on glycolysis-related lncRNAs was constructed to predict the prognosis of ovarian cancer patients, and comprehensive analyses revealed the potential role of this model in OC treatment.

JOURNAL OF OVARIAN RESEARCH (2021)

添加到收藏夹

Article Oncology

Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian Cancer

Nicole E. James et al.

Summary: This study identified novel immune response genes and cell subsets associated with improved high grade serous ovarian cancer patient prognosis, including CTLA-4, LAG-3, T-regs, and ICOS. These findings provide valuable insights into the unique immune microenvironment of ovarian cancer.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano et al.

Summary: The study aimed to evaluate the safety and efficacy of Sabatolimab and spartalizumab in patients with advanced solid tumors. The results showed that the combination of Sabatolimab plus spartalizumab was well tolerated and showed signs of antitumor activity, with the recommended dose for Sabatolimab being 800 mg Q4W, with or without 400 mg spartalizumab Q4W.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Understanding LAG-3 Signaling

Luisa Chocarro et al.

Summary: LAG-3 is a cell surface inhibitory receptor that regulates immunity and is considered a potential target for enhancing anti-cancer immune responses. Its mechanisms of action and relationship with other immune checkpoint molecules are still poorly understood.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Oncology

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points

Janina Swiderska et al.

Summary: Ovarian cancer is a highly fatal cancer in women globally, with immunotherapy playing a significant role in its treatment, particularly targeting immune checkpoints molecules like PD-1/PDL-1. While immune checkpoint-inhibitor therapy has not shown improved prognosis in ovarian cancer, early trials indicate that a combination of anti-PD-1/PD-L1 therapy with targeted therapy may have the potential to enhance responses and outcomes in select patients. Further research is needed to identify the specific patient populations that could benefit from immune checkpoint inhibitors in ovarian cancer treatment.

CANCERS (2021)

添加到收藏夹

Article Oncology

LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer

Lena Seifert et al.

Summary: In this study, the expression pattern of co-stimulatory and inhibitory receptors by tumor-infiltrating T cells in pancreatic ductal adenocarcinoma (PDAC) was investigated. The findings suggest that T cells are enriched in the stromal area of PDAC, with CD8(+) and Th1-polarized CD4(+) T cell infiltration associated with prolonged survival. Additionally, LAG-3 expression by PDAC-infiltrating T cells was correlated with reduced disease-free survival, highlighting the potential of LAG-3 as a prognostic marker and a target for immunotherapeutic strategies.

CANCERS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Ovarian Cancer Immunotherapy and Personalized Medicine

Susan Morand et al.

Summary: Response to immunotherapy in ovarian cancer is limited, but stratification by tumor biomarkers may improve predictiveness. Future directions include utilizing these biomarkers to select ideal candidates, increasing the likelihood of success with immunotherapy in ovarian cancer.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

TIM-3 restrains anti-tumour immunity by regulating inflammasome activation

Karen O. Dixon et al.

Summary: Research demonstrates the crucial role of TIM-3 in regulating dendritic cell (DC) function, with TIM-3 deletion promoting strong anti-tumour immunity by preventing DCs from expressing a regulatory program and facilitating the maintenance of CD8(+) effector and stem-like T cells. The absence of TIM-3 in DCs leads to increased accumulation of reactive oxygen species, resulting in NLRP3 inflammasome activation, and inhibition of inflammasome activation or downstream effector cytokines IL-1 beta and IL-18 abrogates the protective anti-tumour immunity observed with TIM-3 deletion in DCs.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy

Kimiharu Takamatsu et al.

Summary: Targeting inhibitory receptors (IRs) LAG-3, TIM-3, and TIGIT in immunotherapy for human renal cell carcinoma is promising, with individual IR levels serving as potential biomarkers for analysis. The immunogenomic landscape of the disease can be investigated through automated single-cell counting for these IRs.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Obstetrics & Gynecology

Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and GermlineBRCAStatus

Rachel Whitehair et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2020)

添加到收藏夹

Article Oncology

OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody

Hirofumi Ohmura et al.

BRITISH JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas

Christoph Arolt et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

添加到收藏夹

Article Oncology

Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer

Wenjuan Tian et al.

CANCER MEDICINE (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis

Stephanie M. Slevin et al.

JOURNAL OF CROHNS & COLITIS (2020)

添加到收藏夹

Article Oncology

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors

Aung Naing et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Review Medicine, General & Internal

Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives

Fulvio Borella et al.

DIAGNOSTICS (2020)

添加到收藏夹

Article Immunology

Differential expression of TIM-3 in circulation and tumor microenvironment of colorectal cancer patients

Sarah Khalaf et al.

CLINICAL IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer

Jian-Lei Wu et al.

GYNECOLOGIC ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Tim-3 finds its place in the cancer immunotherapy landscape

Nandini Acharya et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Review Oncology

Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation

Shuang Qin et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma

Florian Gebauer et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Identification of key factors associated with early- and late-onset ovarian serous cystadenocarcinoma

Shuang Ma et al.

FUTURE ONCOLOGY (2020)

添加到收藏夹

Review Immunology

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant

Chang Yang et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Review Oncology

LAG-3: from molecular functions to clinical applications

Takumi Maruhashi et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer

Michal Hensler et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Immunology

PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer

Masaaki Sawada et al.

INTERNATIONAL IMMUNOLOGY (2020)

添加到收藏夹

Review Oncology

Ovarian Cancer: An Integrated Review

Christine Stewart et al.

SEMINARS IN ONCOLOGY NURSING (2019)

添加到收藏夹

Article Oncology

TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer

Jitka Fucikova et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Dentistry, Oral Surgery & Medicine

Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients

Hong Wang et al.

JOURNAL OF ORAL PATHOLOGY & MEDICINE (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Shuang Qin et al.

MOLECULAR CANCER (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

Jun Wang et al.

CELL (2019)

添加到收藏夹

Article Immunology

Association of LAG3 genetic variation with an increased risk of PD in Chinese female population

Wenyuan Guo et al.

JOURNAL OF NEUROINFLAMMATION (2019)

添加到收藏夹

Article Oncology

Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer

Emelie Radestad et al.

ONCOIMMUNOLOGY (2019)

添加到收藏夹

Article Immunology

Function of T regulatory type 1 cells is down-regulated and is associated with the clinical presentation of coronary artery disease

Zhendong Zhu et al.

HUMAN IMMUNOLOGY (2018)

添加到收藏夹

Article Immunology

TIM-3 expression identifies a distinctive PD-1+ follicular helper T cell subset, with reduced interleukin 21 production and B cell help function in ovarian cancer patients

Li Li et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2018)

添加到收藏夹

Article Immunology

LAG3+ Regulatory T Cells Restrain Interleukin-23 Producing CX3CR1+ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis

David Bauche et al.

IMMUNITY (2018)

添加到收藏夹

Article Oncology

Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer

Hyun-Soo Kim et al.

GYNECOLOGIC ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer

Ruea-Yea Huang et al.

ONCOIMMUNOLOGY (2017)

添加到收藏夹

Article Oncology

Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression

Weiqun Lu et al.

ONCOTARGET (2017)

添加到收藏夹

Review Oncology

Role of TIM-3 in ovarian cancer

Y. Xu et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma

Nicolas A. Giraldo et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Biology

Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer

M. Li et al.

BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2017)

添加到收藏夹

Article Oncology

Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8+ T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression

Meimei Bu et al.

TUMOR BIOLOGY (2016)

添加到收藏夹

Article Pathology

LAG3 Expression in Active Mycobacterium tuberculosis Infections

Bonnie L. Phillips et al.

AMERICAN JOURNAL OF PATHOLOGY (2015)

添加到收藏夹

Article Oncology

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T-Cells, Which Dampen CD8+ T-cell Antitumor Reactivity

Marco Donia et al.

CANCER RESEARCH (2015)

添加到收藏夹

Article Oncology

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model

Ruea-Yea Huang et al.

ONCOTARGET (2015)

添加到收藏夹

Article Oncology

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

Theodore Kouo et al.

CANCER IMMUNOLOGY RESEARCH (2015)

添加到收藏夹

Article Oncology

PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer

John R. Webb et al.

CANCER IMMUNOLOGY RESEARCH (2015)

添加到收藏夹

Review Immunology

Molecular and cellular insights into T cell exhaustion

E. John Wherry et al.

NATURE REVIEWS IMMUNOLOGY (2015)

添加到收藏夹

Article Immunology

Lymphocyte Activation Gene-3 Expression Defines a Discrete Subset of HIV-Specific CD8+ T Cells That Is Associated with Lower Viral Load

Jose Pena et al.

AIDS RESEARCH AND HUMAN RETROVIRUSES (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T- cells to Be Suppressed In Vivo

Nicholas M. Durham et al.

PLOS ONE (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Expression of Tim-3 in Peripheral Blood of Ovarian Cancer

Jie Wu et al.

DNA AND CELL BIOLOGY (2013)

添加到收藏夹

Article Immunology

Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients

Fu-Jun Li et al.

IMMUNOLOGY LETTERS (2013)

添加到收藏夹

Article Medicine, Research & Experimental

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer

Zhiqiang Guo et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Tim-3 Expression Defines Regulatory T Cells in Human Tumors

Jing Yan et al.

PLOS ONE (2013)

添加到收藏夹

Article Endocrinology & Metabolism

Modulation of Redox Balance Leaves Murine Diabetogenic TH1 T Cells LAG-3-ing Behind

Meghan M. Delmastro et al.

DIABETES (2012)

添加到收藏夹

Article Immunology

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

Taku Okazaki et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2011)

添加到收藏夹

Article Immunology

MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis

Patrice Hemon et al.

JOURNAL OF IMMUNOLOGY (2011)

添加到收藏夹

Review Immunology

T cell exhaustion

E. John Wherry

NATURE IMMUNOLOGY (2011)

添加到收藏夹

Article Oncology

Intratumoral Interleukin-21 Increases Antitumor Immunity, Tumor-infiltrating CD8(+) T-cell Density and Activity, and Enlarges Draining Lymph Nodes

Henrik Sondergaard et al.

JOURNAL OF IMMUNOTHERAPY (2010)

添加到收藏夹

Article Multidisciplinary Sciences

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

Junko Matsuzaki et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)

添加到收藏夹

Article Immunology

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

C Zhu et al.

NATURE IMMUNOLOGY (2005)

添加到收藏夹

Article Immunology

Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells

M Kisielow et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2005)

添加到收藏夹

Article Genetics & Heredity

Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis

Z Zhang et al.

GENES AND IMMUNITY (2005)

添加到收藏夹

Article Immunology

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function

R Zeng et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2005)

添加到收藏夹

Article Immunology

Role of LAG-3 in regulatory T cells

CT Huang et al.

IMMUNITY (2004)

添加到收藏夹

Article Hematology

MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223)

S Andreae et al.

BLOOD (2003)

添加到收藏夹

Article Immunology

The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells

CJ Workman et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.